Form 4: Director Michael R. McMullen Acquires BMY Deferred Units

Bristol Myers Squibb director Michael R. McMullen acquired 577.082 deferred share units as part of director compensation.

Summary

• Director Michael R. McMullen acquired 577.082 Deferred Share Units (DSUs) on March 31, 2026.
• The units were acquired at a price of $60.65 per unit.
• Following this transaction, the director holds a total of 15,556.771 units.
• These units are part of the 1987 Deferred Compensation Plan for Non-Employee Directors and will convert to common stock upon the director's departure from the board or a previously specified date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Demonstrates continued alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified.

Risks

• Value of deferred share units is subject to the market performance of Bristol Myers Squibb common stock.

Future Outlook

The deferred share units will convert to common stock upon the director's cessation of service or at a previously specified future date.

Industry Context

StockSavvy.ai notes that director equity acquisitions via deferred compensation plans are standard corporate governance practices in the pharmaceutical industry, intended to ensure long-term alignment between board members and shareholders.

Comparison to Industry Standards

• The use of deferred share units for non-employee directors is consistent with compensation structures at major pharmaceutical peers like Pfizer and Merck.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard director compensation event.

Next Steps

• Conversion of deferred share units into common stock upon the director's retirement or specified future date.

Key Dates

Keywords

Bristol Myers Squibb, BMY, Director Compensation, Insider Transaction, Deferred Share Units, SEC Form 4